Osteoporosis (OP) is one of the common bone
metabolic diseases that endangers postmenopausal women and the elders. Both excessive
bone resorption caused by osteoclast over-activation and increased oxidative stress are associated with
osteoporosis.
Cinnamtannin B-1 (CB-1) is considered as a high-valued
plant extract monomer due to its
antioxidant properties. However, the mechanism of CB-1 impacts on reducing oxidative stress, inhibiting the production of
reactive oxygen species (ROS) and osteoclast differentiation and preventing
ovariectomy-induced
osteoporosis are still unclear. In this study, the effects of CB-1 on nuclear factor κB (RANKL)-induced osteoclasts formation and differentiation in vitro and the potential
therapeutic effect on
ovariectomy (OVX)-induced
osteoporosis in vivo are investigated. CB-1 was found to inhibit osteoclast formation and
bone resorption function in a dose-dependent manner, and it inhibited specific genes related to osteoclast as well. Micro-CT and histopathological staining showed that CB-1 can effectively prevent OVX-induced
osteoporosis. In addition, CB-1 treatment can effectively inhibit the production of
reactive oxygen species (ROS) in vivo and in vitro. Mechanistically, CB-1 inhibits the activation of osteoclasts by inhibiting the activation of the NF-κB signaling pathway. In conclusion, CB-1 would be able to be used as a promising new drug strategy to inhibit RANKL-induced osteoclastogenesis and prevent
ovariectomy-induced
osteoporosis.